Summit Therapeutics
SMMTSummit Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel oncology therapies that aim to improve patient quality of life and survival.
Earnings
Next report
Aug 10, 2026 (In 4 weeks)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Summit Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel oncology therapies that aim to improve patient quality of life and survival. The company's primary focus is the clinical development of ivonescimab, a first-in-class bispecific antibody designed to combine immunotherapy and anti-angiogenesis effects. Summit operates primarily in licensed territories including North America, Europe, and Japan, targeting serious unmet medical needs in lung and colorectal cancers.
Summit is a late-stage clinical developer of a potential first-in-class PD-1/VEGF bispecific antibody, currently seeking FDA approval for its lead candidate.
Questions, answered.
- What is Summit Therapeutics's market cap?
- Summit Therapeutics (SMMT) has a market capitalization of $12.0B and trades on NASDAQ.
- Who are Summit Therapeutics's competitors?
- Summit Therapeutics's key competitors include BioNTech SE, AstraZeneca, Merck & Co., Inc., and others. These companies compete in similar markets and product categories.
- Who does Summit Therapeutics partner with?
- Summit Therapeutics's notable partners include Akeso, Inc., GORTEC, BioNTech SE, and others.
- Where is Summit Therapeutics headquartered?
- Summit Therapeutics is headquartered in United States of America and employs approximately 105 people. It has been publicly traded since 2015.